A PhII to Evaluate the efficacy, safety and tolerability of AZD5069 in Patients with Uncontrolled Persistant Asthma

Update Il y a 5 ans
Reference: EUCTR2012-001869-33

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To determine the efficacy of 3 different doses of AZD5069 compared with placebo on the rate of severe asthma exacerbations over 6 months in adults with uncontrolled persistent asthma, despite treatment with medium to high dose inhaled corticosteroids (≥fluticasone 500 µg or the equivalent daily) and long acting β2 agonists.


Inclusion criteria

  • Asthma